SUPPLEMENTARY TABLE 1. Characteristics of study cohort*

	CoronaVac (n=197)	BNT162B2 (n=100)	P value†
Age, y	49.03 ± 9.70	46.54 ± 11.28	0.0614
Sex			0.0003
Male	77 (39.1%)	62 (62.0%)	
Female	120 (60.9%)	38 (38.0%)	
Body mass index, kg/m²	23.43 ± 3.27	23.57 ± 3.49	0.7507
Medical co-morbidities			
No. of medical co-morbidities			
None	136 (69.0%)	75 (75.0%)	0.8327
1	39 (19.8%)	15 (15.0%)	
2	13 (6.6%)	7 (7.0%)	
3	8 (4.1%)	3 (3.0%)	
4	0	0	
5	1 (0.5%)	0	
Diabetes mellitus	9 (4.6%)	7 (7.0%)	0.4194
Hypertension	20 (10.2%)	10 (10.0%)	1
Hyperlipidaemia	24 (12.2%)	11 (11.0%)	0.8504
Cardiovascular disease	3 (1.5%)	0	0.5533
Stroke	1 (0.5%)	0	1
Asthma	2 (1.0%)	2 (2.0%)	0.605
Chronic renal disease	1 (0.5%)	0	1
Chronic liver disease or cirrhosis	6 (3.0%)	1 (1.0%)	0.43
History of malignancy‡	10 (5.1%)	1 (1.0%)	0.1062
Systemic lupus erythematosus	1 (0.5%)	0	1
Other autoimmune disease	7 (3.6%)§	1 (1.0%)‖	0.2744
Medication			
Steroid	1 (0.5%)	0	1
Non-steroid immunosuppressant	1 (0.5%)	0	1

* Data are shown as mean ± standard deviation or No. (%), unless otherwise specified
† Fisher's exact test was used to test categorical variables. *t* Test was used to test continuous variables. A P value of <0.05 was considered statistically significant
‡ All without chemotherapy or radiotherapy in the past 6 months
§ Including 1 case of immunoglobulin A nephropathy, 2 cases of non-specific arthritis receiving hydroxychloroquine, 1 case of ankylosing spondylitis receiving ixekizumab, 1 case of rheumatoid arthritis receiving hydroxychloroquine, and 2 cases of ocular myasthenia gravis
‖ Ulcerative colitis receiving treatment with mesalazine

SUPPLEMENTARY TABLE 2. Multivariate analysis on significant variables related to sustained or lost surrogate neutralising antibody (sNAb) at week 12*

	Coefficient	P value	Odds ratio (95% CI)
Age	0.0272	0.2143	1.0276 (0.9844-1.0727)
Male sex	-0.6958	0.1191	0.4987 (0.2079-1.1964)
CoronaVac	-0.5468	0.7087	0.5788 (0.0328-11.0198)
Abbott SARS-CoV-2 IgG			
After dose 1 (≥2 weeks)	1.6661	0.5183	5.2916 (0.0337-830.3325)
After dose 2 (≥2 weeks)	-2.6179	0.0024	0.0730 (0.0135-0.3951)
GenScript cPass surrogate neutralising antibody			
After dose 1 (≥2 weeks)	-0.0096	0.6301	0.9904 (0.9524-1.0300)
After dose 2 (≥2 weeks)	-0.0489	0.0044	0.9523 (0.9208-0.9849)

Abbreviations: 95% CI = 95% confidence interval; IgG = immunoglobulin G; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

* The cohort was dichotomised into whether the sNAb dropped below 30% signal inhibition, which defined lost sNAb. Lost sNAb was treated as event (Y=1), and sustained sNAb is treated as no event (Y=0)